drugset / Trial / NCT01466192
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who relapsed after previous treatment.
Timeline
- Start
- 2012-05
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telaprevir | Small molecule | 750 mg | — |
| Background | Peginterferon alfa-2b | Protein / enzyme biologic | 1.5 ug/kg | — |
| Background | Ribavirin | Small molecule | 400 mg | — |
| Background | Ribavirin | Small molecule | 1000 mg | — |